 SAN DIEGO, May 20, 2021 GLOBE NEWSWIRE -- Reneo Pharmaceuticals, Inc. NASDAQ: RPHM, a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic, mitochondrial diseases, today reported financial results for the quarter ended March 31, 2021 and provided an update on its clinical programs. 